IPO Timeline
Broker Results (T-2)
2020-07-08
Some brokers release in afternoon
Grey Market (T-1)
2020-07-09
Afternoon
HKEX Allotment (T-1)
2020-07-09
Evening
Registrar Allotment (T-1)
2020-07-09
Evening
Listing Day (T)
2020-07-10
First day of trading
Company Overview
| Stock Name | 永泰生物製藥有限公司 - B |
|---|---|
| Stock Code | 06978 |
| Company Full Name | 永泰生物製藥有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事細胞免疫產品的研發、制造及商業化。 |
| Listing Date | 2020-07-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區康定街1號國盛科技園1號樓8層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.eaal.net |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 11.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 28.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 550,000,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 15.48 |
|---|---|
| First Day Open | HK$ 13.4 |
| First Day Change | 40.73% |
| First Day Volume | 73620500.0 |
| First Day Turnover | 1099240000.0 |
Use of Proceeds
| Use of Proceeds | 1、約34.2%的所得款項凈額或350.2百萬港元用于投資EAL正在進行的臨床試驗及商業化； 2、約18.9%的所得款項凈額或193.5百萬港元用于擴展EAL的臨床適應癥（不包括肝癌），包括研發開支及就EAL持續技術創新設立新研發中心的建設成本； 3、約33.2%的所得款項凈額或340.0百萬港元用于投資CAR-T-19及TCR-T在研產品系列的臨床試驗，主要包括研發開支； 4、約8.7%的所得款項凈額或89.1百萬港元用于投資我們產品管線中其他在研產品的開發； 5、約5.0%的所得款項凈額或51.2百萬港元用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
Overall Coordinators (3)
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
海通国际证券有限公司 CE AAF806
Joint Bookrunners (13)
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
海通国际证券有限公司 CE AAF806
农银国际证券有限公司 CE ACX411
交银国际证券有限公司 CE APJ121
招商证券（香港）有限公司 CE AAI650
民银证券有限公司 CE APU820
安信国际证券(香港)有限公司
国泰君安证券（香港）有限公司 CE ABY236
工银国际证券有限公司 CE ARO299
申万宏源证券（香港）有限公司 CE AAC927
ZHONGRONG PT SECURITIES LIMITED CE AAV553
中泰国际证券有限公司 CE BAA855
Joint Lead Managers (18)
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
海通国际证券有限公司 CE AAF806
农银国际证券有限公司 CE ACX411
阿尔法国际证券(香港)有限公司
交银国际证券有限公司 CE APJ121
招商证券（香港）有限公司 CE AAI650
民银证券有限公司 CE APU820
安信国际证券(香港)有限公司
富途证券国际（香港）有限公司 CE AZT137
国泰君安证券（香港）有限公司 CE ABY236
华邦证券有限公司
工银国际证券有限公司 CE ARO299
JOY RICH SECURITIES INVESTMENT LIMITED CE BIH924
申万宏源证券（香港）有限公司 CE AAC927
ZHONGRONG PT SECURITIES LIMITED CE AAV553
中泰国际证券有限公司 CE BAA855
一盈证券有限公司 CE BJB315
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Poly Platinum Enterprises Limited | 155,001,000 HKD | — | 14.10% | — | 6 months | 2021-01-10 |
| 2 | 季洪昌 | 38,742,000 HKD | — | 3.50% | — | 6 months | 2021-01-10 |
| 3 | 天士力(香港)医药投资有限公司 | 76,714,000 HKD | — | 7.00% | — | 6 months | 2021-01-10 |
| 4 | 中国联塑集团控股有限公司 | 38,742,000 HKD | — | 3.50% | — | 6 months | 2021-01-10 |
Directors & Management
| Chairman | 譚錚 |
|---|---|
| Company Secretary | 梁瑞冰 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 譚錚及關連人士(35.07%);鄭鉉哲(26.22%);華潤醫藥集團有限公司(10.00%);張軍政(8.49%);大灣區共同家園發展基金有限公司(6.41%) |
|---|
IPO Timeline
